University of Utah Research Foundation

Myriad Genetics, Inc.

The United States of America As Represented by the Department of Health

The United States of America As Represented by the Secretary of Health

Theradoc, Inc.

Myraid Genetics, Inc.

Theradoc.com, Inc.

Mark H. Skolnick

Donna M. Shattuck-eidens

Andrew P. Futreal

Sean V. Tavtigian

David E. Goldgar

Yoshio Miki

P. Andrew Futreal

Roger W. Wiseman

Mark H Skolnick

Alexander Kamb

Sean V Tavtigian

Donna M Shattuck-Eidens

Roger W Wiseman

P Andrew Futreal

David E Goldgar

Jeff Swenson

Keith D Harshman

Stanley L Pestotnik

William F Harty

Lisa A Cannon-Albright

Jonathan B Olson

Merle A Sande

Bo Lu

Richard J Boekweg

Michael E Baza

David H Teng

Michael A Rubin

William L Perry, Iii

Matthew H Samore

R Scott Evans

David D Eardley

William H Tettelbach

Barry M Stults

Andrew P Futreal

A decision-support system for providing a clinician with real-time patient data specific to each patient that the clinician is to examine in a defined time period. The system including a decision-support module that is configured to generate decision-supported patient data that is specific to each patient that a clinician is to examine in a defined time period. The decision-support module including an inference engine that communicates with a knowledge module and a patient module to generate the decision-supported patient data. In real-time communication with the decision-support module is a user module that is adapted to present the decision-supported patient data in real-time to the clinician in a configuration that assists the clinician in treating each patient. The user module further allowing the clinician to changes elements of the decision-supported patient data and receive new recommendations and medical care suggestions in real-time from the decision-support module.

Systems and methods for communicating between a decision-support system and one or more mobile information devices

Disclosed is a method for delivering decision-supported patient data to a clinician to aid the clinician with the diagnosis and treatment of a medical condition. The method including presenting a patient with questions generated by a decision-support module and gathering patient data indicative of the responses to the questions. Each question presented to the patient is based upon the prior questions presented to and the patient data gathered from the patient. Upon receiving the patient data from the client module, evaluating the patient data at the module to generate decision-supported patient data, this supported patient data includes medical condition diagnoses, pertinent medical parameters for the medical condition, and medical care recommendations for the medical condition. At the client module or a clinician's client module, presenting the clinician with this patient data in either a standardized format associated with a progress note or a format selected by the clinician.

Systems and methods for manipulating medical data via a decision support system

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

17q-linked breast and ovarian cancer susceptibility gene

The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.

Methods for detecting predisposition to cancer at the MTS gene

The present invention relates to mutations in the MKK4 gene in human cancers and their use in the diagnosis and prognosis of human cancer. Specific mutations in the MKK4 gene which are associated with breast, pancreatic, colorectal and testicular cancers have been identified. The invention also relates to the therapy of human cancers which have a mutation in the MKK4 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.

Specific mutations of map kinase 4 (MKK4) in human tumor cell lines

170-linked breast and ovarian cancer susceptibility gene

17Q-linked breast and ovarian cancer susceptibility gene

Germline mutations in the MTS gene

Growing community of inventors

Salt Lake City, UT, United States of America

Mark H Skolnick